Black Rose Indus (514183)
CyclicalFairStock Score: 10/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹131.65 |
| Market Cap | ₹675.69 Cr |
| P/E Ratio | 21.79 |
| ROCE | 18.97% |
| ROE | 13.33% |
| Dividend Yield | 1.29% |
| Profit Growth | -25.51% |
| Debt/Equity | — |
| Sales Growth | -14.31% |
| 52-Week Range | ₹61 — ₹133 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹27.81 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me start with what I like: this is a specialty chemicals business, and the return on capital employed is 18.97%, with return on equity at 13.33%. Those are not terrible numbers. But investing is about the future, and the recent figures point downhill. Sales are down 14.31% and profits are down 25.51%. The latest quarter adds just ₹4 crore net profit on ₹75 crore of sales - a thin margin. The Piotroski F-Score is only 3 out of 9, which tells me the financial health is deteriorating, not improving. Benjamin Graham taught me to buy with a margin of safety. At ₹131.65, the market cap is ₹676 crore, which is 21.79 times earnings. For a company whose earnings are shrinking, that multiple offers little cushion. The price-to-book ratio is 4.73 against a book value of ₹27.81. I am paying nearly five times tangible net worth for a business with falling sales and falling profit. The dividend yield of 1.29% is modest, not enough to compensate for the risks. I also note that the stock sits near its 52-week high of ₹137.95, while the fundamentals are moving in the opposite direction. That is a dangerous disconnect. Price is what you pay; value is what you get. Here, the value seems to be eroding. I cannot rely on debt-equity data because it has not been provided, and that makes me even more cautious; without knowing the leverage, I cannot judge the safety of the balance sheet. This looks like a cyclical or struggling specialty chemical player being priced for perfection. I would rather miss the bounce than lose capital. I need to see stable sales, profit recovery, and an attractive price before I commit. For now, I pass.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer